Literature DB >> 11302867

Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis.

L Vasiliauskiene1, A Wiik, M Høier-Madsen.   

Abstract

OBJECTIVES: To assess the clinical value of several serological markers in Lithuanian patients with rheumatoid arthritis (RA) compared with control patients with rheumatic disease and age matched healthy controls.
METHODS: Serum samples from 96 patients with RA of approximately 8 years' duration, 90 rheumatic disease controls, and 37 healthy subjects were tested. Antikeratin antibody (AKA), antineutrophil cytoplasmic antibody (ANCA), and antinuclear antibody (ANA) titres were estimated by indirect immunofluorescence (IIF) and serum samples positive for ANA and ANCA were further studied by enzyme linked immunosorbent assay (ELISA). IgA and IgM rheumatoid factors (RF) were measured by ELISA.
RESULTS: A positive AKA test was highly specific for RA (diagnostic specificity 97%), being found in 44% of the patients. Although both RF tests had a higher sensitivity, they were less specific for RA. ANCA was detected in 33% of patients with RA but lacked diagnostic specificity. AKA and ANCA were associated with more erosive disease and the presence of extra-articular manifestations. Positivity for AKA, IgA RF, and ANCA was significantly associated with disease activity and worse functional capacity. However, in multiple regression analysis only positivity for AKA was significantly correlated with functional disability (p=0.0001), evaluated by the Steinbrocker functional classification, and no single marker had any relation with radiological damage.
CONCLUSION: Although AKA showed the highest disease specificity, all serological markers studied except ANA exhibited interesting associations with important clinical and paraclinical parameters of RA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302867      PMCID: PMC1753650          DOI: 10.1136/ard.60.5.459

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  45 in total

1.  The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.

Authors:  M Sebbag; M Simon; C Vincent; C Masson-Bessière; E Girbal; J J Durieux; G Serre
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

2.  Comparison of heparin-binding to lactoferrin from human milk and from human granulocytes by means of affinity capillary electrophoresis.

Authors:  N H Heegaard; J Brimnes
Journal:  Electrophoresis       Date:  1996-12       Impact factor: 3.535

3.  Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study.

Authors:  E Röther; T Schochat; H H Peter
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

4.  Myeloperoxidase-mediated iodination in granulocytes.

Authors:  I Olsson; T Olofsson; H Odeberg
Journal:  Scand J Haematol       Date:  1972

5.  Granulocyte-specific antinuclear factors in synovial fluids and sera from patients with rheumatoid arthritis.

Authors:  A Wiik; E Jensen; J Friis
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

6.  IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications.

Authors:  C Jorgensen; M C Legouffe; C Bologna; J Brochier; J Sany
Journal:  Clin Exp Rheumatol       Date:  1996 May-Jun       Impact factor: 4.473

7.  Enzyme-linked immunosorbent assay for determination of IgM rheumatoid factor.

Authors:  M Vejtorp; M Høier-Madsen; P Halberg
Journal:  Scand J Rheumatol       Date:  1979       Impact factor: 3.641

8.  Antineutrophil cytoplasmic antibodies in synovial fluid and in serum of patients with rheumatoid arthritis and other types of synovitis.

Authors:  A Afeltra; G D Sebastiani; M Galeazzi; D Caccavo; G M Ferri; R Marcolongo; L Bonomo
Journal:  J Rheumatol       Date:  1996-01       Impact factor: 4.666

9.  Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis.

Authors:  I E Coremans; E C Hagen; M R Daha; F J van der Woude; E A van der Voort; C Kleijburg-van der Keur; F C Breedveld
Journal:  Arthritis Rheum       Date:  1992-12

10.  Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass.

Authors:  G Cambridge; M Williams; B Leaker; M Corbett; C R Smith
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

View more
  10 in total

Review 1.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

2.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

3.  Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis.

Authors:  Nehir Samanci; Sebahat Ozdem; Halide Akbas; Derya Mutlu; Meral Gultekin; Mehmet Arman; Levent Donmez
Journal:  J Natl Med Assoc       Date:  2005-08       Impact factor: 1.798

4.  Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: a meta-analysis.

Authors:  Xue-Ping Wang; Qian-Yao Cheng; Ming-Ming Gu; Rui-Xue Leng; Yin-Guang Fan; Bao-Zhu Li; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2019-02-27       Impact factor: 2.980

5.  Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis.

Authors:  Anne Friesgaard Christensen; Grith Lykke Sørensen; Kim Hørslev-Petersen; Uffe Holmskov; Hanne Merete Lindegaard; Kirsten Junker; Merete Lund Hetland; Kristian Stengaard-Pedersen; Søren Jacobsen; Tine Lottenburger; Torkell Ellingsen; Lis Smedegaard Andersen; Ib Hansen; Henrik Skjødt; Jens Kristian Pedersen; Ulrik Birk Lauridsen; Anders Svendsen; Ulrik Tarp; Jan Pødenphant; Aage Vestergaard; Anne Grethe Jurik; Mikkel Østergaard; Peter Junker
Journal:  Arthritis Res Ther       Date:  2010-03-08       Impact factor: 5.156

6.  A comparison of performance of anti-cyclic citrullinated peptide 2 and citrullinated protein antibodies in the diagnosis of rheumatoid arthritis in Iranian patients.

Authors:  Elham Aflaky; Saeedeh Shenavandeh; Mohammad Javad Ashraf
Journal:  Rheumatol Int       Date:  2009-08-12       Impact factor: 2.631

7.  Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).

Authors:  K Forslind; M Ahlmén; K Eberhardt; I Hafström; B Svensson
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

8.  Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases.

Authors:  S Dubucquoi; E Solau-Gervais; D Lefranc; L Marguerie; J Sibilia; J Goetz; V Dutoit; A-L Fauchais; E Hachulla; R-M Flipo; L Prin
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

9.  Association between baseline vitamin D metabolite levels and long-term cardiovascular events in patients with rheumatoid arthritis from the CIMESTRA trial: protocol for a cohort study with patient-record evaluated outcomes.

Authors:  M Herly; K Stengaard-Pedersen; K Hørslev-Petersen; M L Hetland; M Østergaard; R Christensen; B B Løgstrup; P Vestergaard; J Pødenphant; P Junker; T Ellingsen
Journal:  BMJ Open       Date:  2017-04-08       Impact factor: 2.692

10.  Serum Th1 and Th17 related cytokines and autoantibodies in patients with Posner-Schlossman syndrome.

Authors:  Jun Zhao; Wenchieh Chen; Xiaosheng Huang; Shiming Peng; Tianhui Zhu; Zhihui Deng; Ping Liang; Hui Chang; Bao Jian Fan
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.